<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877253</url>
  </required_header>
  <id_info>
    <org_study_id>GPMOC201</org_study_id>
    <nct_id>NCT00877253</nct_id>
  </id_info>
  <brief_title>Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer</brief_title>
  <official_title>Open-label, Multicenter, Phase I Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin as a Firstline Treatment in Subjects With Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose of Genexol®-PM plus&#xD;
      Carboplatin and evaluate the efficacy and safety of Genexol®-PM plus Carboplatin regimen in&#xD;
      subjects with advanced ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose&#xD;
      of the combination therapy with Genexol®-PM and Carboplatin and to evaluate the efficacy and&#xD;
      safety of Genexol®-PM when administered with Carboplatin in subjects with advanced ovarian&#xD;
      cancer after debulking surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the MTD and recommended phase II dose of the combination therapy with Genexol-PM and Carboplatin in subjects with advanced ovarian cancer.</measure>
    <time_frame>until either MTD is achieved or maximum planned dose is tested</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (Complete Response (CR) + Partial Response (PR))</measure>
    <time_frame>about 1 year (until end of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>about 1 year (until end of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>about 1 year (until end of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profiles</measure>
    <time_frame>about 1 year (till end of trial)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level One</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level Two</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level Three</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genexol-PM 220mg/㎡, Carboplatin 5AUC</intervention_name>
    <description>Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.</description>
    <arm_group_label>Dose Level One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genexol-PM 260mg/㎡, Carboplatin 5AUC</intervention_name>
    <description>Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.</description>
    <arm_group_label>Dose Level Two</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genexol-PM 300mg/㎡, Carboplatin 5AUC</intervention_name>
    <description>Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.</description>
    <arm_group_label>Dose Level Three</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ≥ 18 years old.&#xD;
&#xD;
          -  Signed informed consent before inclusion.&#xD;
&#xD;
          -  Subjects who have histologically or cytologically confirmed advanced epithelial&#xD;
             ovarian cancer.(FIGO IIIB-IV)&#xD;
&#xD;
          -  Subjects who have measurable disease by RECIST after debulking surgery.&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2.&#xD;
&#xD;
          -  Estimated life expectancy of more than 6 months&#xD;
&#xD;
          -  Subjects who have the clinically acceptable function of blood, kidney and liver at&#xD;
             screening visit&#xD;
&#xD;
               -  Hb ≥ 10g/dl&#xD;
&#xD;
               -  ANC ≥ 1.5×10^9/L&#xD;
&#xD;
               -  Platelet Count ≥ 100×10^9/L&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5×ULN&#xD;
&#xD;
               -  Serum AST and ALT ≤ 2.5×ULN&#xD;
&#xD;
               -  Serum ALP ≤ 2.5×ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5×ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received chemotherapy for ovarian cancer other than debulking&#xD;
             surgery.&#xD;
&#xD;
          -  Subjects who have a history of radiotherapy to pelvis or abdominal cavity&#xD;
&#xD;
          -  Subjects who receive immunotherapy or hormonal therapy for ovarian cancer&#xD;
&#xD;
          -  Subjects who have other malignancies within the past 5 years&#xD;
&#xD;
          -  Subjects who have had a major surgery other than debulking surgery within 2 weeks&#xD;
             prior to the screening/baseline visit&#xD;
&#xD;
          -  Subjects who have a history of metastasis or currently have a metastasis to the&#xD;
             central nervous system(CNS)&#xD;
&#xD;
          -  Subjects who have a preexisting sensory or motor neuropathy of grade ≥ 1 based on NCI&#xD;
             CTCAE V3.0&#xD;
&#xD;
          -  Subjects who have serious medical condition&#xD;
&#xD;
               -  Uncontrolled or severe cardiovascular disease(Ischemic heart disease, myocardial&#xD;
                  infarction within the last 6 months, congestive heart failure)&#xD;
&#xD;
               -  Uncontrollable infection&#xD;
&#xD;
               -  Previous allergic reactions in connection with paclitaxel and carboplatin&#xD;
&#xD;
          -  Subjects who participate another clinical trial within the last 4 weeks before&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Beom Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong Man Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byoung Gie Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Tae Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Health System Severance Hospital</affiliation>
  </overall_official>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <last_update_submitted>June 11, 2012</last_update_submitted>
  <last_update_submitted_qc>June 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

